



R" independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, -N=C(R')$_2$, -NR'-CO-R', -CR'O, -CO_2R', alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R',


wherein the compound is not













































, or



.

2. A compound according to claim 1, wherein

Ar is aryl or heteroaryl, which can be substituted by one or more substituents R';

R^1, Z, Y, R' and R" are as defined in claim 1.

3. A compound according to claim 1, wherein

R^1 is aryl or heteroaryl, which can be substituted by one or more substituents R'

Ar is aryl or heteroaryl, which can be substituted by one or more substituents R';

Z, Y, R' and R" are as defined in claim 1.

4. A compound according to claim 1, wherein

R^1 is aryl, which can be substituted by one or more substituents R'

Ar is aryl or heteroaryl, which can be substituted by one or more substituents R';

Z is H, halogen, -CR"O, $-N(R")_2$, -CN, -C(S)R", $-N=C(R')_2$, $-CO_2R"$, $-NR'CO_2R"$, -CONHR", $-CON(R")_2$, -COSR", -CSNHR", $-CSN(R")_2$, amino, which can be substituted by one or more substituents R';

Y, R' and R" are as defined in claim 1.

5. A compound according to claim 1, wherein

R^1 is aryl or heteroaryl, which can be substituted by one or more substituents R';

Ar is aryl or heteroaryl, which can be substituted by one or more substituents R';

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,

~~methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(ethoxycarbonyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,~~

methyl 3-(2-chloro-6-fluorophenyl)-5-(1 -(3-chlorophenyl)-5-(trifluoromethyl)-1 H-pyrazol-4-yl)isoxazole-4-carboxylate,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(2-(methoxycarbonyl)thiophen-3-yl)-5-(trifluoromethyl)- 1 H-pyrazol-4-yl)isoxazole-4-carboxylate,

(3-(2-chloro-6-fluorophenyl)-5-(1 -(2-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)(piperidin-1-yl)methanone,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-isobutyl-5-(trifluoromethyl)-1H-pyrazol-4-carboxylate,

3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-N-methylisoxazole-4-carboxamide,

ethyl 3-(2-chloro-6-fluorophenyl)-5-(1-(2-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,

isopropyl 3-(2-chloro-6-fluorophenyl)-5-(1-(2-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-phenyl-5-(trifluomethyl)1H-pyrazol-4-yl)isoxazole-4-carboxylate,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3,5-difluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,

3-(2-chloro-6-fluorophenyl)-5-(1-(3-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-N-methylisoxazole-4-carboxamide,

3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-N-methoxy-N-methylisoxazole-4-carboxamide,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1 -(2,2,2-trifluoroethyl)-5-(trifluoromethyl)- 1 H-pyrazol-4-yl)isoxazole-4-carboxylate,

methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3,5-dichlorophenyl)-5-(trifluoromethyl)-1 H-pyrazol-4-yl)isoxazole-4-carboxylate,


methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate,


autoimmune thyroiditis, Grave's disease, rheumatoid arthritis, vitiligo, Crohn's disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjögren's syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host -versus-Graft-Reaction and osteoarthritis.


14. Use of the compounds of the formula (I) as defined in any of claims 1 to 11, and of their pharmacologically tolerable salts in the manufacture of a medicament for treatment of a disease or a therapeutic indication in which the inhibition of interleukin- 17 (IL-17) and/or Interferon-γ (INF-γ) is beneficial.


15. The use of claim 14 wherein the disease or indication is selected from the group consisting of psoriasis, psoriatric arthritis, autoimmune thyroiditis, Grave's disease, rheumatoid arthritis, vitiligo, Crohn's disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjögren's syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host -versus-Graft-Reaction and osteoarthritis.

~~16. A compound according to claim 1, wherein the compound is not~~





Me
N
N
N
O
N
N
Pr-i
Me
N
N
Me


Et
N
N
Me
O
N
N
OH
N
N
Me



, ~~or~~



~~17~~16. A compound according to claim 1, wherein R^1 is aryl, heteroaryl, cycloalkyl, heterocyclyl or alkyl, which can be substituted by one or more substituents R', excluding CH_3.

~~18~~17. A compound according to claim 1, wherein R^1 is aryl, heteroaryl, cycloalkyl, heterocyclyl or selected from the group consisting of $-C_2H_5$, $-CH=CH_2$, $-C\equiv CH$, $-C_3H_7$, $-CH(CH_3)_2$, $-CH_2-CH=CH_2$, $C(CH_3)=CH_2$, $-CH=CH-CH_3$, $-C\equiv C-CH_3$, $-CH_2-$

C≡CH, -C_4H_9, -CH_2-$CH(CH_3)_2$, $CH(CH_3)$-C_2H_5, -$C(CH_3)_3$, -C_5H_{11}, -C_6H_{13}, -C(R')$_3$, -C_2(R')$_5$, -CH_2-C(R')$_3$, -C_3(R')$_7$, -C_2H_4-C(R')$_3$, -C_2H_4-CH=CH_2, -CH=CH-C_2H_5, -CH=$C(CH_3)_2$, -CH_2-CH=CH-CH_3, -CH=CH-CH=CH_2, -C_2H_4-C≡CH, -C≡C-C_2H_5, -CH_2-C≡C-CH_3, -C≡C-CH=CH_2, -CH=CH-C≡CH, -C≡C-C≡CH, -C_2H_4-$CH(CH_3)_2$, -$CH(CH_3)$-C_3H_7, -CH_2-$CH(CH_3)$-C_2H_5, $CH(CH_3)$-$CH(CH_3)_2$, -$C(CH_3)_2$-C_2H_5, -CH_2-$C(CH_3)_3$, -C_3H_6-CH=CH_2, -CH=CH-C_3H_7, -C_2H_4-CH=CH-CH_3, -CH_2-CH=CH-C_2H_5, -CH_2-CH=CH-CH=CH_2, -CH=CH-CH=CH-CH_3, -CH=CH-CH_2-CH=CH_2, -$C(CH_3)$=CH-CH=CH_2, -CH=$C(CH_3)$-CH=CH_2, -CH=CH-$C(CH_3)$=CH_2, -CH_2-CH=$C(CH_3)_2$, $C(CH_3)$=$C(CH_3)_2$, C_3H_6-C≡CH, -C≡C-C_3H_7, -C_2H_4-C≡C-CH_3, -CH_2-C≡C-C_2H_5, -CH_2-C≡C-CH=CH_2, -CH_2-CH=CH-C≡CH, -CH_2-C≡C-C≡CH, -C≡C-CH=CH-CH_3, -CH=CH-C≡C-CH_3, -C≡C-C≡C-CH_3, -C≡C-CH_2-CH=CH_2, -CH=CH-CH_2-C≡CH, -C≡C-CH_2-C≡CH, -$C(CH_3)$=CH-CH=CH_2, -CH=$C(CH_3)$-CH=CH_2, -CH=CH-$C(CH_3)$=CH_2, -$C(CH_3)$=CH-C≡CH, -CH=$C(CH_3)$-C≡CH, -C≡C-$C(CH_3)$=CH_2, -C_3H_6-$CH(CH_3)_2$, -C_2H_4-$CH(CH_3)$-C_2H_5, -$CH(CH_3)$-C_4H_9, -CH_2-$CH(CH_3)$-C_3H_7, -$CH(CH_3)$-CH_2-$CH(CH_3)_2$, -$CH(CH_3)$-$CH(CH_3)$-C_2H_5, -CH_2-$CH(CH_3)$-$CH(CH_3)_2$, -CH_2-$C(CH_3)_2$-C_2H_5, -$C(CH_3)_2$-C_3H_7, $C(CH_3)_2$-$CH(CH_3)_2$, -C_2H_4-$C(CH_3)_3$, -$CH(CH_3)$-$C(CH_3)_3$, -C_4H_8-CH=CH_2, -CH=CH-C_4H_9, -C_3H_6-CH=CH-CH_3, -CH_2-CH=CH-C_3H_7, -C_2H_4-CH=CH-C_2H_5, -CH_2-$C(CH_3)$=$C(CH_3)_2$, -C_2H_4-CH=$C(CH_3)_2$, -C_4H_8-C≡CH, -C≡C-C_4H_9, -C_3H_6-C≡C-CH_3, -CH_2-C≡C-C_3H_7, and -C_2H_4-C≡C-C_2H_5.

~~19~~18. A compound according to claim 1, wherein Z is F, Br, I, CR''O, -N(R'')$_2$, -CN, -C(S)R'', N=C(R')$_2$, -CO_2R'', -NR'CO_2R'', CONHR'', CON(R'')$_2$, -COSR'', -CSNHR'', CSN(R'')$_2$, SO_2-alkyl, SO_2-haloalkyl, -SO_2NHR'', SO_2(NR'')$_2$, amino or SO_2R''.

~~20~~19. A compound according to claim 1, wherein Y is halogen, haloalkyl, or alkyl, which can be substituted by one or more substituents R', excluding CH_3.

~~21~~20. A compound according to claim 1, wherein Y is halogen, haloalkyl, or selected from the group consisting of -C_2H_5, -CH=CH_2, -C≡CH, -C_3H_7, -$CH(CH_3)_2$, -CH_2-CH=CH_2, $C(CH_3)$=CH_2, -CH=CH-CH_3, -C≡C-CH_3, -CH_2-C≡CH, -C_4H_9, -CH_2-$CH(CH_3)_2$, $CH(CH_3)$-C_2H_5, -$C(CH_3)_3$, -C_5H_{11}, -C_6H_{13}, -C(R')$_3$, -C_2(R')$_5$, -CH_2-C(R')$_3$, -C_3(R')$_7$, -C_2H_4-C(R')$_3$, -C_2H_4-CH=CH_2, -CH=CH-C_2H_5, -CH=$C(CH_3)_2$, -CH_2-CH=CH-CH_3, -CH=CH-CH=CH_2, -C_2H_4-C≡CH, -C≡C-C_2H_5, -CH_2-C≡C-CH_3, -C≡C-CH=CH_2, -CH=CH-C≡CH, -C≡C-C≡CH, -C_2H_4-$CH(CH_3)_2$, -$CH(CH_3)$-C_3H_7, -CH_2-$CH(CH_3)$-

C_2H_5, $CH(CH_3)$-$CH(CH_3)_2$, -$C(CH_3)_2$-C_2H_5, -CH_2-$C(CH_3)_3$, -C_3H_6-CH=CH_2, -CH=CH-C_3H_7, -C_2H_4-CH=CH-CH_3, -CH_2-CH=CH-C_2H_5, -CH_2-CH=CH-CH=CH_2, -CH=CH-CH=CH-CH_3, -CH=CH-CH_2-CH=CH_2, -$C(CH_3)$=CH-CH=CH_2, -CH=$C(CH_3)$-CH=CH_2, -CH=CH-$C(CH_3)_2$, $C(CH_3)$=$C(CH_3)_2$, C_3H_6-C≡CH, -C≡C-C_3H_7, -C_2H_4-C≡C-CH_3, -CH_2-C≡C-C_2H_5, -CH_2-C≡C-CH=CH_2, -CH_2-CH=CH-C≡CH, -CH_2-C≡C-C≡CH, -C≡C-CH=CH-CH_3, -CH=CH-C≡C-CH_3, -C≡C-C≡C-CH_3, -C≡C-CH_2-CH=CH_2, -CH=CH-CH_2-C≡CH, -C≡C-CH_2-C≡CH, -$C(CH_3)$=CH-CH=CH_2, -CH=$C(CH_3)$-CH=CH_2, -CH=CH-$C(CH_3)$=CH_2, -$C(CH_3)$=CH-C≡CH, -CH=$C(CH_3)$-C≡CH, -C≡C-$C(CH_3)$=CH_2, -C_3H_6-$CH(CH_3)_2$, -C_2H_4-$CH(CH_3)$-C_2H_5, -$CH(CH_3)$-C_4H_9, -CH_2-$CH(CH_3)$-C_3H_7, -$CH(CH_3)$-CH_2-$CH(CH_3)_2$, -$CH(CH_3)$-$CH(CH_3)$-C_2H_5, -CH_2-$CH(CH_3)$-$CH(CH_3)_2$, -CH_2-$C(CH_3)_2$-C_2H_5, -$C(CH_3)_2$-C_3H_7, $C(CH_3)_2$-$CH(CH_3)_2$, -C_2H_4-$C(CH_3)_3$, -$CH(CH_3)$-$C(CH_3)_3$, -C_4H_8-CH=CH_2, -CH=CH-C_4H_9, -C_3H_6-CH=CH-CH_3, -CH_2-CH=CH-C_3H_7, -C_2H_4-CH=CH-C_2H_5, -CH_2-$C(CH_3)$=$C(CH_3)_2$, -C_2H_4-CH=$C(CH_3)_2$, -C_4H_8-C≡CH, -C≡C-C_4H_9, -C_3H_6-C≡C-CH_3, -CH_2-C≡C-C_3H_7, and -C_2H_4-C≡C-C_2H_5.

21. A compound according to claim 1, wherein R^1 is not piperidinyl.